Regional Quality Control of Coagulation Assay Procedures (Normotest, Simplastin-A and Thrombotest)

Summary

The report is based on the first 8 months’ operation of an extended regional quality control program involving 20 hospital laboratories in the Stockholm area. The test material was a commercially available lyophilized human reference plasma containing uniformly reduced levels of factors II, VII and X, and optimal concentrations of fibrinogen and factor V. Each participant received 2 batches of the test material with different activity at each 4-week period. Participants were requested to analyze the specimens, independently and in duplicates, along with ordinary patient samples three times weekly during each period. The levels of the factors in the batches were changed in each period. The total number of reported results was 3113. The statistical analysis of values included the calculation of means and variances within and between different thromboplastins (Normotest, Simplastin-A, Thrombotest), different techniques (venous and capillary blood, automatic and manual end-point determination), and laboratories classified according to the category and number of personnel and of performed coagulation tests. Systematic differences between thromboplastins, techniques and laboratories, even using the same type of thromboplastin, contributed a significantly greater amount than within-laboratory random variation to the total variation of determinations. The obtained results indicate the urgency of the quality control of coagulation activity tests.

• References

• 1 Barnett R. N. 1968; Medical significance of laboratory results. American Journal of Clinical Pathology 50: 671.
• 2 Copeland B. E, Skendzel L. P, Barnett R. N. 1972; Interlaboratory comparison of university hospital referee laboratories and community hospital laboratories, using results of the 1968 College of American Pathologists Clinical Chemistry Survey. American Journal of Clinical Pathology 58: 281.
• 3 Fisher L. M, Humphries B. L. 1966; Statistical quality control of rabbit brain thromboplastin for clinical use in the prothrombin time determination. American Journal of Clinical Pathology 45: 148.
• 4 van Horn P. 1968; Quality control of prothrombin determinations, normal and abnormal prothrombin activity levels. American Journal of Medical Technology 34: 73.
• 5 Kahan J. 1974 Evaluation of an extended regional quality control program as tested on the measurement of hemoglobin (to be published).
• 5 Koepke J. A. 1970; The 1969 survey of prothrombin time. American Journal of Clinical Pathology 54: 502.
• 6 Miale J. B, Kent J. W. 1973; Performance characteristics of reference thromboplastins. American Journal of Clinical Pathology 60: 453.
• 8 Miale J. B, Lafond D. J. 1967; 1963 prothrombin time survey, College of American Pathologists, Standard Committee, Subcommittee of Coagulation. American Journal of Clinical Pathology 47: 40.
• 9 Skendzel L. P. 1970; Guidelines for the design of laboratory surveys. American Journal of Clinical Pathology 54: 437.
• 10 Straumfjord jr. J. V, Copeland B. E. 1965; Clinical chemistry quality control values in thirty-three university medical school hospitals. Preliminary report. American Journal of Clinical Pathology 44: 252.
• 11 Sub-Committee for the Control of Anticoagulant Therapy 1964; Report to the M. R. C. Working Party on Anticoagulant Therapy in Coronary Thrombosis. Control of anticoagulant therapy: Postal comparison between five centres. Journal of Clinical Pathology 17 531.
• 12 Tonks D. B. 1963; A study of the accuracy and precision of clinical chemistry determinations in 170 Canadian laboratories. Clinical Chemistry 09: 217.
• 13 Zucker S, Brosius E, Cooper G. R. 1970; One-stage prothrombin time survey. American Journal of Clinical Pathology 53: 340.